title: Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group.
abstract: We conducted a retrospective survey of multiple myeloma (MM) patients who underwent reduced-intensity conditioning allogeneic stem cell transplantation (RIST) at 11 hospitals participating in the Japan Myeloma Study Group. Forty-five patients (median age, 53 years) were included in this study. The conditioning regimen consisted of a fludarabine-based regimen in 24 patients and a regimen based on total body irradiation (1-2 Gy) in 18 patients. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and tacrolimus in 28 and 17 patients, respectively. All patients showed myeloid engraftment. Complete chimerism was obtained in 42 patients. Grade II to IV acute GVHD developed in 28 (65%) of 43 patients evaluated, and chronic GVHD developed in 31 (76%) of 41 patients. Early death before day 100 was observed in 4 patients (8.8%). A complete response (CR) was obtained in 12 patients. The factors affecting overall survival were severe acute GVHD and the response after RIST. To date, 18 patients are alive, with 9 patients remaining in CR at a median follow-up of 25 months. The overall and progression-free survival rates at 3 years were 38.5% and 18.8%, respectively. These observations suggest that RIST is feasible with reliable donor engraftment and relatively low transplantation-related mortality in Japanese MM patients.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 620-9566, Japan. simazaki@koto.kpu-m.ac.jp
authors.forename: Chihiro
authors.initials: C
authors.lastname: Shimazaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujii
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Takaaki
authors.initials: T
authors.lastname: Chou
authors.forename: Miki
authors.initials: M
authors.lastname: Nishimura
authors.forename: Hideki
authors.initials: H
authors.lastname: Asaoku
authors.forename: Shuichi
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ishii
authors.forename: Tadao
authors.initials: T
authors.lastname: Ishida
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Iida
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takagi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Takatsuki
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006086:Graft vs Host Disease; D006306:Health Surveys; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous